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lopidogrel and
alcium-Channel Antagonists
nother Drug–Drug
nteraction for the Ever-Wary Clinician?*
eal S. Kleiman, MD, FACC
ouston, Texas, and New York, New York
he medical management of patients with coronary artery
isease is currently dominated by strategies to alter lipid
evels and to inhibit platelet aggregation and activation. In
act, one can make a very strong argument that coronary
rtery stenting would never have achieved its current level of
opularity and success had it not been for the pioneering
ork done by Colombo et al. (1) using the thienopyridine
iclopidine. Ticlopidine has been almost universally replaced
y clopidogrel, a second-generation thienopyridine that is
onsiderably better tolerated. Despite clopidogrel’s success
or patients receiving intracoronary stents and for patients
ith acute coronary syndromes, its use is hampered by the
onsistent finding that as many as 1 of 4 patients receiving
lopidogrel have little evidence of antiplatelet response to
he drug (2–4). The phenotype of clopidogrel “resistance”
as been associated with an increased risk of cardiovas-
ular events (3,5) and of stent thrombosis; several pro-
pective investigations are being performed to verify these
ndings.
See page 1557
Clopidogrel is a pro-drug and is converted in the liver by
he members of the cytochrome P450 (CYP) family (pre-
ominantly the 3A and 2C groups) to a series of metabo-
ites, the last of which, the thiol metabolite, is an antagonist
f the platelet purinergic receptor known as P2Y12 (6). As
eviewed elsewhere, ligation of P2Y12 by the active metab-
lite of clopidogrel prevents adenoside diphosphate (ADP)
rom activating the receptor and prevents a chain of events
hat would otherwise lead to platelet shape change, secre-
ion, and aggregation. Among the many tests that have been
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Methodist DeBakey Heart and Vascular Center, Houston, Texas; and
he Weill Cornell Medical College, New York, New York. Dr. Kleiman receivedm
esearch support from BMS Sanofi-Aventis, Eli Lilly Inc., and The Medicines
ompany.roposed to assess clopidogrel’s biologic activity, a recent
ddition has been the development of assays for vasodilator
timulated phosphoprotein (VASP). The VASP assay de-
eloped by Schwarz et al. (7) appears to capture most of the
ctivity of P2Y12 and has the advantage that, unlike
unctional assays such as platelet aggregation, it is pathway-
pecific for P2Y12 activation. When ADP ligates P2Y12,
i protein signaling pathways reduce intracellular levels of
yclic adenosine monophosphate (cAMP), which in turn
eads to decreased phosphorylation of VASP. Because
hosphorylation inactivates VASP, high levels of dephos-
horylated VASP reflect high levels of P2Y12 occupancy by
DP whereas high levels of phosphorylated VASP reflect
lockade of P2Y12. The relationship is generally regarded
s being linear. For clinical purposes, levels of VASP
hosphorylation are indexed for maximal VASP phosphor-
lation (stimulated by prostaglandin E1) and are reported as
he platelet reactivity index (PRI), or VASP phosphoryla-
ion index.
In this issue of the Journal, Siller-Matula et al. (8)
ssessed whether calcium-channel antagonists, specifically
erapamil and a number of dihydropyridines, altered the
ffect of clopidogrel on platelets in patients undergoing
oronary arterial stenting. The interaction between calcium-
hannel antagonists and the metabolism of other drugs is
ell documented. Diltiazem and verapamil are classified as
moderate” CYP3A inhibitors, and evidence points to the
ihydropyridines as inhibitors of CYP3A as well (9). In fact,
iltiazem is occasionally used with transplant patients to
llow the use of smaller (i.e., less expensive) doses of
yclosporine (7,10). Siller-Matula et al. (8) measured VASP
evels in 200 consecutive patients undergoing stent implan-
ation and found that the PRI was significantly higher
implying less clopidogrel effect on platelets) among patients
ho were receiving calcium-channel antagonists compared
ith patients who were not. In parallel, electrical impedance
easurements of platelet aggregation showed less inhibition
n patients who were treated with calcium-channel antago-
ists. Incubation with calcium-channel blockers of blood
amples from patients treated with clopidogrel had no effect
n platelet activity (thus excluding a direct effect of the drugs),
nd multivariable analyses suggested that use of calcium-
hannel antagonists was an independent predictor of dimin-
shed clopidogrel activity. The composite rate of clinical events
ver 6 months was also higher among patients treated with
alcium-channel antagonists.
Although this evidence should be regarded as preliminary
several more direct tests of the hypothesis, such as mea-
urement of serum levels of the active metabolite of clopi-
ogrel and more direct assessment of CYP3A4 activity,
ere not performed), the findings should impart important
essons. The average age of patients undergoing coronary
tenting is in the mid-60s. Patients in this age group often
ave a variety of diseases and are usually treated with
ultiple medications. The potential for drug–drug interac-
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ombinations present for a particular patient can be calcu-
ated as the binomial coefficient of the number of medica-
ions the patient is taking. For a patient taking n medica-
ions, there are 1⁄2 n(n-1) potential pairings of drugs. In fact,
n 2006 and 2007, in the EVENT (Evaluation of Drug-
luting Stents and Ischemic Events) registry of unselected
atients undergoing stent implantation, the median num-
er of medications per patient was 5 (excluding over-the-
ounter medications and supplements), yielding 10 po-
ential pairings per patient. A recent study (11), involving
,601 patients over the age of 65 years using a total of
1,180 prescribed drugs, indicated that there were 24
ombinations per person. In 46% of patients, 1 or more
nown drug– drug interactions could be identified (11). In
hat study, the number of combinations leading to subthera-
eutic effects was approximately equal to the number lead-
ng to potential adverse drug reactions. The findings of
iller-Matula et al. (8) should, if nothing else, remind us
hat patients undergoing coronary artery stenting have
ultiple drug interactions that can alter the activity of some
f the drugs upon whose effects the success of the procedure
epends, and that we often take for granted. Some examples
nclude the interaction of aspirin with nonsteroidal anti-
nflammatory drugs (12) and with the histamine H2 recep-
or blocker ranitidine (13), the interaction of clopidogrel
ith atorvastatin (14), and with the proton-pump inhibitor
meprazole (15), and even the possible interaction of
lopidogrel with quantities of caffeine that are found in
ommercially available coffee (16).
Several caveats nonetheless should be kept in mind when
onsidering whether and to what degree this study should
nfluence clinical practice. First and foremost, the clinical
mplications of these findings are not clear. Platelets per-
orm multiple functions in the thrombotic process. Al-
hough the finding that atorvastatin can interfere with the
ffect of clopidogrel, probably through competition for
YP3A4 (14), has been replicated in ex vivo studies, other
tudies dispute the presence of the interaction (17), and
linical observations from several databases have failed to
upport the hypothesis that rates of myocardial infarction or
tent thrombosis are elevated among patients treated with
torvastatin and clopidogrel compared to clopidogrel alone
17–20). It is theoretically possible that the databases reflect
balance between the effects of atorvastatin in preventing
yocardial infarction, on the one hand, and its diminishing
he in vivo effect of clopidogrel, on the other. However, it is
lso possible that the degree to which the biologic effect of
lopidogrel is decreased is not clinically significant and/or
hat the wrong measure of platelet activity was tested in the
x vivo studies. Another issue that is important in interpret-
ng the findings of the current study is that of statistical
onfounding. It is likely that in the current study, patients
ith more severe disease (and therefore at high risk) were
ore likely to receive calcium-channel blockers than pa-ients who did not receive them. Although correction forge, gender, and diabetes mellitus did not appear to dimin-
sh the independent predictive ability of calcium-channel
lockade, it is possible that unmeasured confounders played
n important role here by increasing platelet activation or
ecreasing clopidogrel metabolism. Finally, it is worth
ointing out that, although this study was not designed with
dequate power to assess clinical events, those events that
ccurred more frequently among patients treated with
alcium-channel antagonists consisted largely of revascular-
zation, an event whose frequency would not be expected to
e influenced by clopidogrel.
Thus, while the findings of Siller-Matula et al. (8) cannot
e considered as providing definitive evidence for a clinical
nteraction between calcium-channel antagonists and clopi-
ogrel, they certainly should give the clinician reason for
ause. Patients are frequently treated with multiple medi-
ations, many of which are costly, noxious, and occasionally
ownright hazardous. Calcium-channel antagonists provide
sterling example of this issue. In the 2002 American
ollege of Cardiology/American Heart Association guide-
ines for the management of patients with stable angina
ectoris (21) and the 2007 guidelines for the management of
cute coronary syndromes (22), nondihydropyridines have
eceived class I and IIa status, respectively, for the manage-
ent of symptoms. It is important for clinicians to ask
hemselves whether the drugs they prescribe are being given
o relieve symptoms (for which there is modest evidence), or
olely to modify the disease process (for which there is no
vidence), and to recognize the potential to exchange
nwittingly the disease-modifying properties of some drugs,
uch as clopidogrel, for ill-defined or absent properties of
ther drugs.
eprint requests and correspondence: Dr. Neal S. Kleiman,
ethodist DeBakey Heart Center, Cardiology, The Methodist
ospital, 6565 Fannin, F-1035, Houston, Texas 77030. E-mail:
kleiman@tmhs.org.
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